News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Theraclone Sciences, Inc. Announces Positive Top-Line Data From Phase 1 Trial of Therapeutic Antibody for the Treatment of Human Cytomegalovirus Infection



4/2/2013 9:44:11 AM

SEATTLE--(BUSINESS WIRE)--Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced positive top-line data from its Phase 1 trial of TCN-202, which was discovered using Theraclone’s I-STARTM platform. TCN-202 is a broadly protective, fully human monoclonal antibody, being developed for the treatment of human cytomegalovirus (CMV) infection. TCN-202 was well tolerated throughout the study, with no dose-limiting toxicities or serious adverse events observed, and demonstrated a favorable immunogenicity profile.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES